Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from #2 last year to #1, Ionis was recognized for its industry-leading innovation, talented employees and strong values-based culture.

“Being recognized as the #1 top employer by Science in only our second year of eligibility is a testament to the extraordinary people at Ionis who drive our innovative science forward,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “United by a patient-centric purpose, we are proud to foster a unique culture where our people can be at their best as they advance groundbreaking medicines for people living with serious diseases.”

The Science and Science Careers’ 2026 Top Employers Survey findings were based on approximately 5,100 responses from readers of Science and other survey invitees. Respondents to the web-based survey were asked to rate companies based on 24 characteristics that cover categories such as corporate image, financial prowess, leadership and direction and work culture/environment.

“Since Ionis was founded more than three decades ago, curiosity and courage have defined how we push the boundaries of science,” said Eric Swayze, Ph.D., executive vice president, research, Ionis. “Our culture encourages people to ask difficult questions, challenge conventional thinking and listen and learn from one another. This freedom to explore, which is rooted in mutual respect and collaboration, is what attracts top talent and makes Ionis an empowering place to do meaningful work for patients in need.”

The complete Science magazine feature and rankings can be found here. To learn more about Ionis, including career opportunities, visit Ionis.com/careers.

About Ionis Pharmaceuticals, Inc.

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Media gallery

About The Author
Business Wire